Sparabombe Scilla, Vitali Lucia, Nori Alessandra, Berlin Ricarda Sara, Mazur Marta, Orsini Giovanna, Putignano Angelo
Department of Clinical Sciences and Stomatology, Faculty of Medicine, Polytechnic University of Marche, Palace "Murri", Floor No. 3, Via Tronto 10, 60126 Ancona, Italy.
Special and Surgical Stomatology Department, "Ospedali Riuniti" Hospital of Ancona, Via Conca 2, 60126 Ancona, Italy.
Int J Dent. 2014;2014:475859. doi: 10.1155/2014/475859. Epub 2014 Sep 1.
Objectives. Bisphosphonates related osteonecrosis of the jaw (BRONJ) is a pathological condition characterized by bone exposure or latent infection in patients treated with the drug. The aim of the study is to monitor the BRONJ level of risk health in patients with cancer, according to a preventive clinical protocol, which is firstly aimed at reducing risk factors such as the periodontal infections. Materials and Methods. 10 patients participated in the protocol and were evaluated at baseline and after 3 and 18 months of treatment with bisphosphonates, through full mouth plaque and bleeding scores (FMPS and FMBS), clinical attachment level (CAL) measurement, and the occurrence of osteonecrosis. Results. The mean plaque and bleeding were reduced and the CAL has not shown significant changes and in no cases was there manifestation of BRONJ. Conclusion. The protocol proved crucial for the maintenance of good oral health conditions by eliminating the risk of BRONJ during the observation period.
目的。双膦酸盐相关颌骨坏死（BRONJ）是一种病理状况，其特征为接受该药物治疗的患者出现骨暴露或潜在感染。本研究的目的是根据一项预防性临床方案，监测癌症患者中BRONJ的健康风险水平，该方案首先旨在降低诸如牙周感染等风险因素。材料与方法。10名患者参与了该方案，并在基线时以及使用双膦酸盐治疗3个月和18个月后，通过全口菌斑和出血评分（FMPS和FMBS）、临床附着水平（CAL）测量以及骨坏死的发生情况进行评估。结果。平均菌斑和出血情况有所减少，CAL未显示出显著变化，且在任何病例中均未出现BRONJ表现。结论。该方案被证明对于在观察期内通过消除BRONJ风险来维持良好的口腔健康状况至关重要。
